GlassScriptPhysician profile
Adam M Roth
NPI 1457550428
$209,718.43
in general payments reported to CMS, 2019-2025
21 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78K · 2020: $26K · 2021: $19K · 2022: $19K · 2023: $20K · 2024: $34K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $53K · Consulting Fee: $7,460 · Food and Beverage: $4,177 · Travel and Lodging: $3,640 · Education: $52.88.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $53,240.00 |
| Consulting Fee | $7,460.00 |
| Food and Beverage | $4,177.30 |
| Travel and Lodging | $3,640.31 |
| Education | $52.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $83,523.53 | 2019-2021 | |
| Alkermes, INC. | $42,229.87 | 2021-2025 | Lybalvi, Aristada |
| Abbvie INC. | $39,370.93 | 2021-2024 | Vraylar |
| Sunovion Pharmaceuticals INC. | $20,827.38 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $16,506.55 | 2019-2024 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,970.44 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,573.18 | 2019-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Jazz Pharmaceuticals INC. | $1,010.35 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $516.16 | 2019-2025 | Rexulti, Nuedexta |
| Vanda Pharmaceuticals INC. | $476.58 | 2019-2024 | Fanapt, Hetlioz |
| Avanir Pharmaceuticals, INC. | $203.79 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $146.14 | 2019-2025 | Trintellix |
| Axsome Therapeutics, INC. | $96.56 | 2022-2024 | Auvelity, Sunosi |
| Alfasigma USA, INC. | $62.65 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $58.04 | 2023-2024 | Austedo Xr, Austedo |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $44.45 | 2024 | Nuplazid |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $33.12 | 2019 | |
| Shire North American Group INC | $26.54 | 2019 | |
| Eisai INC. | $16.70 | 2021 | |
| Owp Pharmaceuticals, INC. | $13.90 | 2019 | |
| Adlon Therapeutics L.P. | $11.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.